Featured Publications
Distinct neural networks predict cocaine versus cannabis treatment outcomes
Lichenstein S, Kohler R, Ye F, Potenza M, Kiluk B, Yip S. Distinct neural networks predict cocaine versus cannabis treatment outcomes. Molecular Psychiatry 2023, 28: 3365-3372. PMID: 37308679, PMCID: PMC10713861, DOI: 10.1038/s41380-023-02120-0.Peer-Reviewed Original ResearchMeSH KeywordsCannabisCocaineCocaine-Related DisordersCognitive Behavioral TherapyHumansMaleOpioid-Related DisordersSubstance-Related DisordersTreatment OutcomeConceptsConnectome-based predictive modelingCognitive behavior therapyCognitive behavioral therapySubstance use disordersCannabis abstinenceNeural mechanismsBehavior therapyDistinct neural networksComputer-based trainingCannabis use disorderFMRI scanningNeural predictorsStudy 1Study 2Treatment outcomesContingency managementPrior workComparison subjectsNetwork strengthUse disordersNovel treatment targetsAbstinenceIndependent samplesCocaine abstinenceTreatment responders
2021
Clinical prediction of extra-medical use of prescription pain relievers from a representative United States sample
Thompson CL, Alcover KC, Yip SW. Clinical prediction of extra-medical use of prescription pain relievers from a representative United States sample. Preventive Medicine 2021, 149: 106610. PMID: 33989674, DOI: 10.1016/j.ypmed.2021.106610.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnalgesics, OpioidCross-Sectional StudiesHumansOpioid-Related DisordersPainPrescriptionsUnited StatesConceptsExtra-medical usePrescription pain relieversRepresentative United States sampleHealth administrative dataAnnual cross-sectional surveyHistory of depressionCross-sectional surveyPast-year useReceiver operator curveLogistic regression modelsUnited States population sampleUS National SurveyPharmacy recordsOpioid dependencePrescription opioidsPrescription painPeak incidencePain relieversClinical utilityPsychiatric historyDrug useOperator curveClinical predictionMedical guidanceMedical services
2019
Dissociable neural substrates of opioid and cocaine use identified via connectome-based modelling
Lichenstein SD, Scheinost D, Potenza MN, Carroll KM, Yip SW. Dissociable neural substrates of opioid and cocaine use identified via connectome-based modelling. Molecular Psychiatry 2019, 26: 4383-4393. PMID: 31719641, PMCID: PMC7214212, DOI: 10.1038/s41380-019-0586-y.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBrainCocaineCocaine-Related DisordersConnectomeHumansMagnetic Resonance ImagingOpioid-Related DisordersConceptsBrain statesDissociable neural substratesMultiple brain statesSubstance use outcomesHealthy comparison subjectsWhole-brain approachFMRI scanningFrontoparietal networkNeural substratesSubstance use treatmentNeural mechanismsDifferent brain statesFurther clinical relevanceDefault modeFMRI dataSubject replicationTreatment approachesReduced connectivityUse outcomesComparison subjectsNetwork strengthUse disordersSensory networksTreatment respondersSensory connectivityDouble‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use
Carroll KM, DeVito EE, Yip SW, Nich C, Sofuoglu M. Double‐Blind Placebo‐Controlled Trial of Galantamine for Methadone‐Maintained Individuals With Cocaine Use Disorder: Secondary Analysis of Effects on Illicit Opioid Use. American Journal On Addictions 2019, 28: 238-245. PMID: 31165574, PMCID: PMC9078084, DOI: 10.1111/ajad.12904.Peer-Reviewed Original ResearchConceptsMethadone-maintained individualsOpioid useSecondary analysisMultiple drugsConcurrent cocaine dependenceTrial of galantaminePlacebo-controlled trialDouble-blind placeboIllicit opioid useRandomized clinical trialsCocaine use disorderGalantamine's effectFuture trialsClinical trialsUrine specimenUrine specimensUse disordersOpioidsCholinesterase inhibitorsMaintenance settingCocaine useCocaine dependencePlaceboConcurrent useGalantamineConnectome-Based Prediction of Cocaine Abstinence
Yip SW, Scheinost D, Potenza MN, Carroll KM. Connectome-Based Prediction of Cocaine Abstinence. American Journal Of Psychiatry 2019, 176: 156-164. PMID: 30606049, PMCID: PMC6481181, DOI: 10.1176/appi.ajp.2018.17101147.Peer-Reviewed Original ResearchMeSH KeywordsAdultBehavior TherapyBrainCholinesterase InhibitorsCocaine-Related DisordersCognitionConnectomeExecutive FunctionFemaleFunctional NeuroimagingGalantamineHumansIndividualityMachine LearningMagnetic Resonance ImagingMaleMiddle AgedNeural PathwaysOpiate Substitution TreatmentOpioid-Related DisordersPrognosisRewardTreatment OutcomeConceptsConnectome-based predictive modelingCocaine use disorderUse disordersBrain-based predictorsLarge-scale neural networksFunctional MRI dataCocaine abstinenceExecutive controlReward responsivenessIndividual differencesBaseline cocaine usePosttreatment assessmentConnectivity strengthHeterogeneous sampleAbstinenceIndependent samplesNovel interventionsCanonical networksSpecific behaviorsCocaine useSignificant correspondenceDisordersTreatment outcomesNetwork strengthMRI data
2018
Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder
Carroll KM, Nich C, Frankforter TL, Yip SW, Kiluk BD, DeVito EE, Sofuoglu M. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder. Drug And Alcohol Dependence 2018, 192: 264-270. PMID: 30300800, PMCID: PMC6203294, DOI: 10.1016/j.drugalcdep.2018.08.019.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAnhedoniaAnxietyDepressionFemaleHumansMaleNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPatient DropoutsTreatment OutcomeConceptsOpioid use disorderOral naltrexoneUse disordersAffective symptomsVoucher-based contingency managementDysphoric symptomsAffective distressOral naltrexone treatmentMultiple baseline characteristicsBaseline characteristicsNaltrexone treatmentHigh riskNaltrexoneSomatic symptomsSymptomsContingency managementTreatmentHigh rateDistressSubstantial evidenceTrialsTheoretical benefitsDisordersAffective discomfortParticipantsCan neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research
Moningka H, Lichenstein S, Worhunsky PD, DeVito EE, Scheinost D, Yip SW. Can neuroimaging help combat the opioid epidemic? A systematic review of clinical and pharmacological challenge fMRI studies with recommendations for future research. Neuropsychopharmacology 2018, 44: 259-273. PMID: 30283002, PMCID: PMC6300537, DOI: 10.1038/s41386-018-0232-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBrainHumansMagnetic Resonance ImagingNeuroimagingOpioid-Related DisordersResearch DesignConceptsOpioid use disorderOpioid epidemicTreatment responseTask-based fMRI paradigmsUrgent public health problemMedication-assisted treatmentPrescription opioid usersCurrent opioid epidemicPublic health problemEvidence-based treatmentsPaucity of literatureHeroin cuesOpioid medicationsRelapse rateOpioid systemOpioid usersFuture neuroimaging studiesSignificant individual variabilityHealthcare costsWithdrawal effectsHealthy individualsHealth problemsSystematic reviewExtended abstinenceNeuroimaging studiesThe Cholinergic System as a Treatment Target for Opioid Use Disorder
Jensen KP, DeVito EE, Yip S, Carroll KM, Sofuoglu M. The Cholinergic System as a Treatment Target for Opioid Use Disorder. CNS Drugs 2018, 32: 981-996. PMID: 30259415, PMCID: PMC6314885, DOI: 10.1007/s40263-018-0572-y.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcholineAnalgesics, OpioidAnimalsCholinergic AgentsHumansNon-Neuronal Cholinergic SystemOpioid-Related DisordersConceptsCholinergic systemUse disordersTreatment targetsOpioid use disorder epidemicCentral nervous system functionTreatment of OUDEffects of acetylcholineOpioid use disorderTobacco use disorderNervous system functionOpioid medicationsDegrade acetylcholineCurrent treatmentOpioid overdosesPreclinical studiesMedicationsAcetylcholineCholinesterase inhibitorsAlzheimer's diseaseNew treatmentsAccidental deathGlobal healthTreatmentOUDDisease